http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Concert Pharmaceuticals Reports First Quarter 2019 Financial Results
-
Concert Pharma (CNCE) Appoints Hoiland to Board
-
Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors
-
Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019
-
Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
-
Concert Pharma (CNCE) Commences Phase 1 Multiple-Ascending Dose Trial of CTP-692 as Adjunctive Treatment for Schizophrenia
-
Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
-
Concert Pharma (CNCE) Confirms Decision from Patent Trial and Appeal Board in IPR Proceeding
-
Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding
-
Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference
-
Concert Pharma (CNCE) Begins Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
-
Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
-
Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting
-
Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs
-
Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019
-
Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting
-
Concert Pharma (CNCE) Begins Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
-
Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
-
Concert Pharma (CNCE) Reports Complete Enrollment of 12mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata
-
Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata
-
Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia
-
Concert Pharma (CNCE) Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata
-
Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata
-
Concert Pharmaceuticals to Participate at Upcoming Investor Conferences
-
Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine
-
Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update
-
Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018
-
Concert Pharma (CNCE) Announces Amended Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
-
Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
-
Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update
-
Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
-
Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
-
Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences
-
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
-
Concert Pharmaceuticals Present at Upcoming Investor Conferences
-
Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
-
Concert Pharma (CNCE) Announces Advancement of Novel Drug Candidate in Schizophrenia
-
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia
-
Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018
-
Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
-
Pre-Open Movers 1/12: (ARDM) (WATT) (EXAS) (FCEL) (FB) (TMHC) (More..)
-
Concert Pharma (CNCE) Announces FDA Granted Fast Track Designation to its CTP-543 for Treatment of Alopecia Areata
-
FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia Areata
-
Concert Pharma (CNCE) Reports Patent Trial and Appeal Board Denies Petition on '335 Petition
-
Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
-
Concert Pharmaceuticals, Inc. (Nasdaq: CNCE) to Ring The Nasdaq Stock Market Closing Bell
-
Bayer CropScience and Flagship Ventures Form Strategic Innovation Partnership to Fund Leading-Edge Agriculture Ventures
-
Concert Pharmaceuticals, Inc. [CNCE] to Ring The NASDAQ Stock Market Opening Bell

